Wennerberg, Krister

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal

Computational Drug Discovery MethodsBioinformatics and Genomic Networks

Cited by 845

Serine phosphorylation negatively regulates RhoA in vivo

Ellerbroek, S. M., Wennerberg, K., & Burridge, K. (2003) · Journal of Biological Chemistry

Protein Kinase Regulation and GTPase SignalingCellular Mechanics and Interactions

Cited by 315

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 234

Methods for High-throughput Drug Combination Screening and Synergy Scoring

He, L., Kulesskiy, E., Saarela, J., Turunen, L., Wennerberg, K., Aittokallio, T., & Tang, J. (2018) · Methods in Molecular Biology

Computational Drug Discovery MethodsCancer Cells and Metastasis

Cited by 232

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingPancreatic and Hepatic Oncology Research

Cited by 231

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Malani, D., Kumar, A., Brück, O., Kontro, M., Yadav, B., Hellesøy, M., Kuusanmäki, H., Dufva, O., Kankainen, M., Eldfors, S., et al. (2022) · Cancer Discovery

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 193

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 149

XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC

Arthur, W. T., Ellerbroek, S. M., Der, C. J., Burridge, K., & Wennerberg, K. (2002) · Journal of Biological Chemistry

Protein Kinase Regulation and GTPase SignalingCellular transport and secretion

Cited by 137

Exploration of databases and methods supporting drug repurposing: a comprehensive survey

Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics

Computational Drug Discovery MethodsBiomedical Text Mining and Ontologies

Cited by 131

Breeze: an integrated quality control and data analysis application for high-throughput drug screening

Potdar, S., Ianevski, A., Mpindi, J.-P., Bychkov, D., Fiere, C., Ianevski, P., Yadav, B., Wennerberg, K., Aittokallio, T., Kallioniemi, O., et al. (2020) · Bioinformatics

Computational Drug Discovery MethodsCell Image Analysis Techniques

Cited by 102

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 65

ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors

Kaipio, K., Chen, P., Roering, P., Huhtinen, K., Mikkonen, P., Östling, P., Lehtinen, L., Mansuri, N., Korpela, T., Potdar, S., et al. (2020) · The Journal of Pathology

Ovarian cancer diagnosis and treatmentCancer Cells and Metastasis

Cited by 54

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

Laine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · Cancer Research

DNA Repair MechanismsBreast Cancer Treatment Studies

Cited by 54

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Pietarinen, P. O., Pemovska, T., Kontro, M., Yadav, B., Mpindi, J. P., Andersson, E. I., Majumder, M. M., Kuusanmäki, H., Koskenvesa, P., Kallioniemi, O., et al. (2015) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 25

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Pietarinen, P. O., Eide, C. A., Ayuda-Durán, P., Potdar, S., Kuusanmäki, H., Andersson, E. I., Mpindi, J. P., Pemovska, T., Kontro, M., Heckman, C. A., et al. (2017) · Oncotarget

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

Adnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14